What is on the horizon for cancer breakthroughs? Through the intersection of biology and technology we are collecting more necessary data from humans, analyzing this data more quickly and accurately and speeding up the progression of early cancer detection and prevention. Because of this more lives will be saved, the quality of the life of the patient will be improved and life spans will be extended.
Join us in this interactive, virtual event where we will look at:
- The RNA, DNA, Protein and Liquid biopsies in cancer research
- The Cellular aspect of targeting cancer cells
- The medical work that can get done through the use of AI Technology
- What is the future of cancer research and finding a cure
Moderator- Steve Collens is CEO of MATTER, the healthcare technology incubator and innovation center. MATTER opened in February 2015 and nurtures entrepreneurs and innovators building next-generation health IT, medical device, diagnostic and biopharma technologies. MATTER has worked with more than 700 healthcare technology ventures and the company partners with dozens of industry-leading companies, health systems and universities.
Steven is also senior advisor at Pritzker Group Venture Capital. Prior to assuming his current role, Steven was senior vice president at Pritzker Group, the investment firm led by Tony and J.B. Pritzker. In that capacity, he led the team that created 1871, the #1 ranked private business incubator in the world. He previously worked at Abbott in a variety of domestic and international functions, including product management, policy and public affairs. In 2005, Steven helped found ConstantWellness.com to give patients control over their health data and allow healthcare providers to coordinate care of their patients. Prior to Abbott, Steven served as legislative assistant to U.S. Senator Carol Moseley-Braun.
Steven holds an MBA from Northwestern University’s Kellogg School of Management and a BA from Washington University in St. Louis. He serves on the boards of 1871, Hubbard Street Dance Chicago and the Chicago High School for the Arts, and is a member of ChicagoNEXT, Mayor Lori Lightfoot’s council on technology and innovation. He is also a Leadership Greater Chicago fellow and a member of the Economic Club of Chicago and the Commercial Club of Chicago
Panelist – Syed Alam is Founder & CEO of accentedge LLC. In a career spanning over 30 years of proven leadership in entrepreneurship, innovation, technology, media and philanthropy he has led several companies to leadership positions in their respective markets. Mr. Alam has also led organizations within iconic multinational corporations such as AbbVie, Miller Brewing, US Bank, Rockwell Automation and Ecolab to transform into more agile and competitive market leaders. A lifelong enthusiast of technology and its application to make the world a better place by improving lives, he is leading the way in providing opportunities of a better future to youth around the world by providing access to education, healthcare, and jobs through accentedge Foundation. A leader in Chicago’s entrepreneurial and technology ecosystem, he is a member of Executives Club of Chicago and MATTER a leading healthcare incubator.
Mr. Alam holds a Master of Business Administration degree from Marquette University and dual Bachelor of Business Administration degree in Management Information Systems and Finance from the University of Wisconsin-Milwaukee in addition to Executive Management education in Digital Transformation, Innovation, and Strategy from MIT.
Panelist- Dr. Azra Raza is the Chan Soon-Shiong Professor of Medicine and Director of the MDS Center at Columbia University. A practicing oncologist seeing 30-40 cancer patients weekly, she also directs a basic cancer research lab with hundreds of original publications in high profile journals. She worked with President Clinton designing Breakthrough Developments in Science and Technology and with VP Joe Biden for the Cancer Moonshot initiative. Her latest book, THE FIRST CELL: And the human costs of pursuing cancer to the last was published in October 2019. Her life is devoted to early detection and prevention of cancer.
Panelist – Seema Rego, Performance driven executive with extensive experience supporting clinical partnerships, business development, and market access strategy and execution for molecular diagnostics and medical device organizations. Seema specializes in working with key cross-functional stakeholders to integrate clinical, economic utility and real-world evidence studies to support diagnostic development, approval and launch strategies.
Through regular communication and the building and management of relationships with payers, with regulatory authorities and with executive leadership, she consistently improves market share, annual revenue, quality and compliance.